<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Management of patients with nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (NICM) and <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) remains challenging </plain></SENT>
<SENT sid="1" pm="."><plain>The role of catheter ablation for VT continues to evolve for these patients </plain></SENT>
<SENT sid="2" pm="."><plain>Prior reports have described the location of the arrhythmogenic substrate for patients with NICM to be frequently located along the basal left ventricle, with an epicardial predilection </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, predictors for identifying whether mapping the endocardium or epicardial surface of the heart have been identified for improved success of VT ablation in this patient population </plain></SENT>
<SENT sid="4" pm="."><plain>This chapter will review the latest advances in catheter ablation of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in patients with NICM </plain></SENT>
</text></document>